翰森制药(03692) - 2021 - 年度财报

Revenue and Financial Performance - The sales revenue of innovative drugs reached approximately RMB 4.202 billion, representing a year-on-year growth of about 168.9%, increasing its share of total revenue from 18.0% to 42.3%[5] - In 2021, the company's revenue reached RMB 9,935,141, an increase of 14.3% from RMB 8,690,234 in 2020[12] - Total revenue for the reporting period was approximately RMB 9.935 billion, an increase of about 14.3% compared to the previous year[17] - Profit for the period was approximately RMB 2.713 billion, reflecting a year-on-year increase of about 5.6%[17] - The company's total equity rose to RMB 20,028,845 thousand in 2021, up from RMB 17,875,598 thousand in 2020, reflecting a stronger financial position[167] - The company reported a total comprehensive income of RMB 2,511,499 thousand for 2021, compared to RMB 1,590,713 thousand in 2020, showing improved overall performance[163] - The net profit for the year was RMB 2,712,902, compared to RMB 2,568,907 in 2020, reflecting a growth of 5.6%[12] - Basic earnings per share for 2021 was RMB 0.46, compared to RMB 0.44 in 2020, indicating a growth in profitability per share[161] Research and Development - The company has a strong focus on R&D, continuously increasing investment and establishing a comprehensive R&D platform[4] - Research and development expenses in 2021 were RMB 1,797,012, an increase of 43.6% from RMB 1,252,246 in 2020[12] - The number of R&D personnel increased to approximately 1,650, with over ten new innovative drug projects entering clinical stages[17] - The company has 36 ongoing clinical projects, with over 25 innovative drugs in clinical stages[28] - The company aims to enhance its R&D capabilities and efficiency, focusing on innovative product development to increase the revenue contribution from innovative drug products[43] Product Development and Approvals - Eleven new products were approved for market during the reporting period, including two innovative drugs for new indications[4] - The innovative drug Amelot (Ametinib Mesylate Tablets) was approved for a new indication in first-line treatment of non-small cell lung cancer during the reporting period[20] - The innovative drug Hengmu (Amitriptyline) received drug registration approval from the National Medical Products Administration in June 2021[8] - The innovative drug Amel (Amitriptyline) was included in the updated national medical insurance catalog in December 2021[8] - The innovative drug Hengmu (艾米替諾福韋片) was approved for chronic hepatitis B treatment in June 2021[28] Financial Position and Assets - The total assets of the company as of December 31, 2021, were RMB 27,160,171, up from RMB 20,792,060 in 2020[13] - Cash and cash equivalents at year-end totaled RMB 14,702,056 thousand, significantly higher than RMB 4,284,970 thousand in 2020, indicating strong liquidity[165] - The company's asset-liability ratio was approximately 26.3% as of December 31, 2021, compared to 14.0% as of December 31, 2020[39] - The company reported a total revenue of RMB 3,300,082,000 before tax, up from RMB 3,098,299,000 in the previous year, indicating a growth of about 6.5%[171] Corporate Governance and Management - The company has established various professional committees, including the Audit Committee, Remuneration Committee, and Strategy and Development Committee, to enhance governance and oversight[63] - The company has appointed Ms. Zhong Huijuan as both the Chairperson and CEO, leveraging her extensive knowledge and experience in the Chinese pharmaceutical industry[56] - The Audit Committee, consisting of three independent non-executive directors, reviewed the consolidated financial statements for the year ended December 31, 2021, confirming compliance with applicable accounting standards and listing rules[64] - The company has established a three-year service contract with each executive director and a three-year appointment letter with independent non-executive directors, ensuring compliance with corporate governance codes[57] Environmental, Social, and Governance (ESG) - The company’s ESG rating improved from BBB to A in the latest MSCI report[8] - The company established an Environmental, Social, and Governance (ESG) committee in 2021 to enhance its ESG management[15] - The board established an Environmental, Social, and Governance (ESG) committee on June 28, 2021, to oversee compliance and initiatives[114] - The ESG Committee identified climate change risks and developed response measures during its meeting in the reporting period[71] Collaborations and Partnerships - The company engaged in significant collaborations, including an exclusive licensing agreement with SCYNEXIS for the commercialization of Ibrexafungerp in China, which is a novel antifungal drug[33] - The company established a joint venture with Cormorant Asset Management, completing a USD 72 million Series A financing[8] - The company actively pursued external collaborations, including partnerships with Keros and Olix Pharmaceuticals to enhance its innovative drug pipeline[34][35] Market and Customer Base - Revenue from the oncology product portfolio reached approximately RMB 5.581 billion, accounting for about 55.2% of total revenue[18] - Revenue from the anti-infection product portfolio was approximately RMB 1.503 billion, representing about 15.1% of total revenue[19] - Revenue from the central nervous system disease product portfolio was approximately RMB 1.678 billion, accounting for about 16.9% of total revenue[19] - Revenue from the metabolic and other product portfolio was approximately RMB 1.273 billion, representing about 12.8% of total revenue[19] Shareholder Information - Major shareholder Stellar Infinity holds 3,900,000,000 shares, representing 65.85% of the total shares[127] - Apex Medical, owned by Mr. Cen Jun Da, holds 950,000,000 shares, accounting for 16.04% of the total shares[127] - The company has maintained a public float of 16.21%, which is below the minimum requirement accepted by the Stock Exchange[132] Compliance and Legal Matters - The company has not violated any relevant laws and regulations that would significantly impact its business operations during the year ended December 31, 2021[111] - The company has appropriate directors' liability insurance to protect against potential claims[131] - The independent auditor's report confirms that the consolidated financial statements reflect the company's financial position accurately as of December 31, 2021[150]